Guardant Health has acquired MetaSight Diagnostics for $59 million upfront, with an additional $90 million tied to future regulatory and commercial milestones, as it looks to expand its multi-disease detection capabilities beyond oncology.
MetaSight develops liquid biopsy diagnostics using a mass spectrometry–based multi-omics approach—including metabolomics, lipidomics, and proteomics—to identify disease biomarkers in blood samples. Its pipeline includes tests for colorectal cancer, liver fibrosis, myocardial infarction, diabetic kidney disease, and pancreatic and lung tumors.
The acquisition complements Guardant’s existing blood-based colorectal cancer screening efforts and supports its broader strategy to develop diagnostics across cardiovascular, renal, neurodegenerative, and autoimmune conditions.